These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 16713148

  • 1. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD, Patil Y, Panyam J.
    Int J Pharm; 2006 Aug 31; 320(1-2):150-6. PubMed ID: 16713148
    [Abstract] [Full Text] [Related]

  • 2. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y, Sadhukha T, Ma L, Panyam J.
    J Control Release; 2009 May 21; 136(1):21-9. PubMed ID: 19331851
    [Abstract] [Full Text] [Related]

  • 3. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
    Liu Y, Pan J, Feng SS.
    Int J Pharm; 2010 Aug 16; 395(1-2):243-50. PubMed ID: 20472049
    [Abstract] [Full Text] [Related]

  • 4. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
    Niu G, Castro CH, Nguyen N, Sullivan SM, Hughes JA.
    J Drug Target; 2010 Jul 16; 18(6):468-76. PubMed ID: 20059301
    [Abstract] [Full Text] [Related]

  • 5. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux.
    Chavanpatil MD, Khdair A, Gerard B, Bachmeier C, Miller DW, Shekhar MP, Panyam J.
    Mol Pharm; 2007 Jul 16; 4(5):730-8. PubMed ID: 17705442
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
    Jin C, Bai L, Wu H, Tian F, Guo G.
    Biomaterials; 2007 Sep 16; 28(25):3724-30. PubMed ID: 17509678
    [Abstract] [Full Text] [Related]

  • 7. The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells.
    Jin C, Wu H, Liu J, Bai L, Guo G.
    J Clin Pharm Ther; 2007 Feb 16; 32(1):41-7. PubMed ID: 17286788
    [Abstract] [Full Text] [Related]

  • 8. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 9. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
    Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, Hao L, Duan C, Jia L, Liu G, Liu Y.
    Biomaterials; 2011 Dec 21; 32(35):9444-56. PubMed ID: 21903258
    [Abstract] [Full Text] [Related]

  • 10. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
    Ji X, Gao Y, Chen L, Zhang Z, Deng Y, Li Y.
    Int J Pharm; 2012 Jan 17; 422(1-2):390-7. PubMed ID: 22001531
    [Abstract] [Full Text] [Related]

  • 11. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition.
    Ling G, Zhang P, Zhang W, Sun J, Meng X, Qin Y, Deng Y, He Z.
    J Control Release; 2010 Dec 01; 148(2):241-8. PubMed ID: 20727928
    [Abstract] [Full Text] [Related]

  • 12. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs.
    Dong Y, Feng SS.
    Biomaterials; 2005 Oct 01; 26(30):6068-76. PubMed ID: 15894372
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Oct 01; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 14. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
    Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP.
    Drug Deliv; 2012 Nov 01; 19(8):363-70. PubMed ID: 23030458
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
    Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, Préat V.
    J Control Release; 2009 Jan 05; 133(1):11-7. PubMed ID: 18950666
    [Abstract] [Full Text] [Related]

  • 16. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 05; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 17. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
    Baek JS, Cho CW.
    Int J Pharm; 2015 Jan 30; 478(2):617-24. PubMed ID: 25510604
    [Abstract] [Full Text] [Related]

  • 18. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C, Pan J, Lu W, Zhang M, Zhou L, Tian J.
    Anticancer Drugs; 2009 Oct 30; 20(9):807-14. PubMed ID: 19696655
    [Abstract] [Full Text] [Related]

  • 19. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
    Niu X, Zou W, Liu C, Zhang N, Fu C.
    Drug Dev Ind Pharm; 2009 Nov 30; 35(11):1375-83. PubMed ID: 19832638
    [Abstract] [Full Text] [Related]

  • 20. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
    Limtrakul P, Siwanon S, Yodkeeree S, Duangrat C.
    Phytomedicine; 2007 Jun 30; 14(6):381-9. PubMed ID: 17467965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.